TrueLab TrueLab Care
Evidence reviews · DOI-cited sources · research use only
Research 13 Nov 2026 · 3 min read · 3 sources

The peptide that came out of a lizard: how exendin-4 started the incretin class

Every weekly GLP-1 injection on the market descends from a molecule found in the saliva of a venomous desert lizard in 1992. The story is usually told as a curiosity. It is better told as a case study in how a research observation becomes a drug, and how long that takes.

TL

TrueLab Research Team

Reviewed 13 Nov 2026 · Summarises peer-reviewed literature · Not medical advice

Key takeaways

  • Exendin-4 was isolated from Gila monster venom in 1992 by John Eng, an endocrinologist at the Bronx VA hospital[^1].
  • It shares about half its sequence with human GLP-1 but is resistant to DPP-4, so it lasts hours rather than minutes.
  • Eng's employer declined to patent it; he filed himself in 1993 and spent three years finding a company willing to develop it[^1].
  • The synthetic version, exenatide, became the first GLP-1 receptor agonist approved by the FDA in 2005, thirteen years after discovery[^2].
  • Every later compound in the class, including the weekly ones, is an answer to the problem exendin-4 posed: how to make GLP-1 signalling last.

The Gila monster is a slow, heavy lizard native to the deserts of the American southwest. It eats a few large meals a year and survives the gaps on stored fat. Its venom had been studied since the 1980s because of a clinical observation: people bitten by one sometimes developed inflammation of the pancreas, which suggested something in the venom was acting on that organ.

In 1992 John Eng, an endocrinologist working at the Veterans Affairs hospital in the Bronx, isolated a 39-amino-acid peptide from the venom and named it exendin-41.

What made it interesting

Exendin-4 shares roughly 53% of its sequence with human GLP-1, the gut hormone that stimulates insulin release after meals. The overlap was enough that it bound and activated the human GLP-1 receptor. The difference was enough that the enzyme DPP-4, which destroys native GLP-1 within two minutes, could not cut it. Exendin-4 lasted hours.

That combination, same receptor, much longer life, is the entire premise of the drug class that followed. A molecule that mimics GLP-1 but survives in circulation can lower glucose and reduce appetite for an extended period from a single injection.

The thirteen years in between

From venom to approval

Years after the 1992 isolation

Isolation (1992) 1992 Patent filed by Eng (1993) 1993 Licensed to Amylin (1996) 1996 FDA approval as exenatide (2005) 2005

Golden Goose Award citation [1]; FDA approval record [2]. Chart by TrueLab Care.

The part of the story that rarely gets told is how close it came to not happening. Eng's employer saw no commercial value in a lizard peptide and declined to patent it. He filed the application himself in 1993 and spent the next three years approaching pharmaceutical companies, none of which were interested1.

In 1996, at an American Diabetes Association meeting in San Francisco, he caught the attention of a scientist from Amylin Pharmaceuticals, a small company that licensed the compound. A synthetic version, exenatide, went through clinical development and was approved by the FDA in 2005 as the first GLP-1 receptor agonist2. Thirteen years from isolation to licence, four of them spent looking for anyone who would take it.

From hours to a week

Exenatide needed injecting twice daily. The next two decades of chemistry were spent extending that. Liraglutide added a fatty-acid chain to bind albumin and reached once daily. Semaglutide refined the chain and the peptide backbone to reach once weekly3. Tirzepatide added a second receptor. Retatrutide added a third.

Every one of those molecules is a descendant of the observation that a lizard's venom contained something that behaved like a durable GLP-1. None of them would exist in their current form if the first had not demonstrated that extended GLP-1 receptor agonism was both possible and useful in humans.

Why the story matters for a research reader

Two lessons travel well.

The first is about provenance. Exendin-4 was a natural product, found by looking carefully at a biological curiosity, and it took a decade of synthesis and trials to become a drug. The modern compounds are entirely synthetic and were designed, not found. The literature for each is correspondingly different: the lizard peptide has a discovery story, the designed peptides have design papers.

The second is about time. Thirteen years from a validated mechanism to an approved drug, for a compound that worked. Retatrutide's discovery paper was published in 2022; its filing is planned for 2027. That is fast by the standards of the class, and it is still half a decade.

References

  1. 1. Golden Goose Award Awardee: John Eng. Diabetes medication from Gila monster venom. goldengooseaward.org 2013 www.goldengooseaward.org ↩
  2. 2. U.S. Food and Drug Administration Byetta (exenatide) injection: approval letter, NDA 021773. FDA 2005 www.accessdata.fda.gov ↩
  3. 3. Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry 2015 ; 58(18):7370-7380 doi:10.1021/acs.jmedchem.5b00726 ↩

This article summarises published research for educational purposes. It is not medical advice and does not describe permitted uses of any product. Compounds discussed are supplied strictly for in-vitro laboratory research and are not for human or animal consumption.

Continue reading

All The Science →